الصحة السمنة الطب القلبية
NEJM
NEJM

@NEJM

2 تغريدة 2 قراءة Nov 12, 2023
Twitter
In patients w/ cardiovascular disease & overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8 mos. Full SELECT trial results: nej.md
#AHA23 @AHAScience
nej.md/465pj91

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes | NEJM

Original Article from The New England Journal of Medicine — Semaglutide and Cardiovascular Outcomes...
@AHAScience Editorial: SELECTing Treatments for Cardiovascular Disease — Obesity in the Spotlight nej.md
nej.md/47nketM

SELECTing Treatments for Cardiovascular Disease — Obesity in the Spotlight | NEJM

Editorial from The New England Journal of Medicine — SELECTing Treatments for Cardiovascular Disease...

التصنيفات

الصحة السمنة الطب القلبية

لم تظهر جميع التغريدات؟

جاري تحميل الاقتراحات...